SMO and medulloblastoma: A large majority of sporadic medulloblastomas and basal cell carcinomas also exhibit hyperactive Hh signaling (in a ligand-independent fashion) due to mutations in Hh pathway components including, PTCH, SMO, and occasionally Suppressor of Fused (SUFU), a negative regulator of the Hh pathway [19].